PMID- 25288062
OWN - NLM
STAT- MEDLINE
DCOM- 20150622
LR  - 20151119
IS  - 0151-9638 (Print)
IS  - 0151-9638 (Linking)
VI  - 141
IP  - 10
DP  - 2014 Oct
TI  - [Capecitabine-induced subacute cutaneous lupus: a case report].
PG  - 593-7
LID - S0151-9638(14)00482-7 [pii]
LID - 10.1016/j.annder.2014.06.011 [doi]
AB  - BACKGROUND: More than 100 drugs have been registered as inducing subacute 
      cutaneous lupus erythematosus (SCLE). Recently, some types of chemotherapy have 
      also been incriminated. If SCLE develops in a setting of neoplasia, two 
      possibilities should be considered: it is either a paraneoplastic syndrome or it 
      is caused by the chemotherapy, thus calling for important decisions on the 
      benefit/risk of stopping potentially effective medication. We report a case of 
      SCLE induced by Xeloda (capecitabine). PATIENTS AND METHODS: A 50-year-old female 
      patient consulted with an annular erythematosquamous and pruriginous eruption, 
      predominantly on areas of the body exposed to sunlight, occurring 4 months after 
      the initiation of capecitabine for advanced colon cancer. She had presented 
      systemic lupus erythematosus (SLE) for many years, which was not treated, was not 
      progressive and had no cutaneous manifestations. The appearance of the cutaneous 
      lesions, positivity for anti-SSA antibodies and the histological aspect led to 
      diagnosis of SCLE. The lesions were resistant to treatment with 
      hydroxychloroquine and systemic corticosteroids, but disappeared after 
      discontinuation of capecitabine, suggesting chemotherapy-induced SCLE. 
      DISCUSSION: Some types of chemotherapy such as capecitabine may reveal or induce 
      SCLE lesions, whether or not there is a previous history of SLE. Cases of 
      chemotherapy-induced cutaneous lupus reported to the French pharmacovigilance 
      agency are rare, but this side effect must be recognised due to the constantly 
      rising use of this type of anticancer agent.
CI  - Copyright (c) 2014 Elsevier Masson SAS. All rights reserved.
FAU - Fongue, J
AU  - Fongue J
AD  - Service de dermatologie, CHU La Timone, 13005 Marseille, France; Service de 
      medecine interne, centre de competence PACA Ouest pour la prise en charge des 
      pathologies auto-immunes systemiques, CHU de la Conception, 147, boulevard 
      Baille, 13005 Marseille, France.
FAU - Meunier, B
AU  - Meunier B
AD  - Service de medecine interne, centre de competence PACA Ouest pour la prise en 
      charge des pathologies auto-immunes systemiques, CHU de la Conception, 147, 
      boulevard Baille, 13005 Marseille, France.
FAU - Lardet, D
AU  - Lardet D
AD  - Cabinet de dermatologie, 47B, avenue Marechal-Foch, 83390 Cuers, France.
FAU - Dicostanzo, M-P
AU  - Dicostanzo MP
AD  - Service de medecine interne, centre de competence PACA Ouest pour la prise en 
      charge des pathologies auto-immunes systemiques, CHU de la Conception, 147, 
      boulevard Baille, 13005 Marseille, France.
FAU - Rouby, F
AU  - Rouby F
AD  - Pharmacovigilance, hopital Salvator, 13009 Marseille, France.
FAU - Terrier, J-P
AU  - Terrier JP
AD  - Laboratoire d'anatomopathologie, 219, rue Revel, 83000 Toulon, France.
FAU - Harle, J-R
AU  - Harle JR
AD  - Service de medecine interne, centre de competence PACA Ouest pour la prise en 
      charge des pathologies auto-immunes systemiques, CHU de la Conception, 147, 
      boulevard Baille, 13005 Marseille, France.
FAU - Richard, M-A
AU  - Richard MA
AD  - Service de dermatologie, CHU La Timone, 13005 Marseille, France.
FAU - Chiche, L
AU  - Chiche L
AD  - Service de medecine interne, centre de competence PACA Ouest pour la prise en 
      charge des pathologies auto-immunes systemiques, CHU de la Conception, 147, 
      boulevard Baille, 13005 Marseille, France. Electronic address: 
      laurent.chiche@ap-hm.fr.
LA  - fre
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
TT  - Lupus cutane subaigu induit par la capecitabine : un cas.
DEP - 20140806
PL  - France
TA  - Ann Dermatol Venereol
JT  - Annales de dermatologie et de venereologie
JID - 7702013
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Adverse Drug Reaction Reporting Systems
MH  - Antimetabolites, Antineoplastic/*adverse effects/therapeutic use
MH  - Capecitabine
MH  - Colonic Neoplasms/*drug therapy
MH  - Deoxycytidine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Diagnosis, Differential
MH  - Female
MH  - Fluorouracil/adverse effects/*analogs & derivatives/therapeutic use
MH  - France
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/diagnosis
MH  - Middle Aged
OTO - NOTNLM
OT  - Capecitabine
OT  - Capecitabine
OT  - Chemotherapy
OT  - Chimiotherapie
OT  - Induced cutaneous lupus erythematosus
OT  - Lupus cutane induit
OT  - Lupus erythemateux subaigu
OT  - Subacute cutaneous lupus erythematosus
EDAT- 2014/10/08 06:00
MHDA- 2015/06/24 06:00
CRDT- 2014/10/08 06:00
PHST- 2014/02/11 00:00 [received]
PHST- 2014/04/08 00:00 [revised]
PHST- 2014/06/19 00:00 [accepted]
PHST- 2014/10/08 06:00 [entrez]
PHST- 2014/10/08 06:00 [pubmed]
PHST- 2015/06/24 06:00 [medline]
AID - S0151-9638(14)00482-7 [pii]
AID - 10.1016/j.annder.2014.06.011 [doi]
PST - ppublish
SO  - Ann Dermatol Venereol. 2014 Oct;141(10):593-7. doi: 10.1016/j.annder.2014.06.011. 
      Epub 2014 Aug 6.